Carol S. Lim

Carol S. Lim, PhD

Languages spoken: English

Academic Information

Departments Primary - Molecular Pharmaceutics

Carol Lim, PhD, is Interim Chair and Professor in the Departments of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah and a member of the Cell Response and Regulation Program at Huntsman Cancer Institute.

Lim studies the development of novel cancer therapeutics (gene therapies, protein/peptide therapies). She focuses on developing new therapies for ovarian cancer and chronic myeloid leukemia. She also has interests in breast cancer and melanoma. She is a member of the Women's Disease Oriented Team.

Lim received a bachelor's degree from Purdue University, Indiana, and a PhD from the University of California, San Francisco. Her postdoctoral training was at the National Institutes of Health, National Cancer Institute.

Education History

Undergraduate Purdue University
 BS
Doctoral Training University of California, San Francisco
 PhD
Postdoctoral Fellowship NIH/National Cancer Institute, Laboratory of Receptor Biology and Gene Expression
 Postdoctoral Fellow

Selected Publications

Journal Article

  1. Lim CS, Hunt CA (1994). Sequential staining of short oligonucleotides in polyacrylamide gels with ethidium bromide and methylene blue. Biotechniques, 17(4), 626, 628.
  2. Dixon AS, Lim CS (2010). The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain. Biotechniques, 49(1), 519-24.
  3. Guy RH, Kalia YN, Lim CS, Nonato LB, Turner NG (1996). Drug smuggling- creative ways to cross biological barriers. Chem Br, 32(7), 42-45.
  4. Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimpi AA, Cheatham TE 3rd, Lim CS (2011). Disruption of Bcr-Abl coiled coil oligomerization by design. J Biol Chem, 286(31), 27751-60.
  5. Baumann CT, Lim CS, Hager GL (1998). Simultaneous visualization of the yellow and green forms of the green fluorescent protein in living cells. J Histochem Cytochem, 46(9), 1073-6.
  6. Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O'Hare T, Deininger MW, Lim CS (2015). A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia, 29(8), 1668-75.
  7. Lim CS, Baumann CT, Htun H, Xian W, Irie M, Smith CL, Hager GL (1999). Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras. Mol Endocrinol, 13(3), 366-75.
  8. Baumann CT, Ma H, Wolford R, Reyes JC, Maruvada P, Lim C, Yen PM, Stallcup MR, Hager GL (2001). The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol Endocrinol, 15(4), 485-500.
  9. Lim CS, Jabrane-Ferrat N, Fontes JD, Okamoto H, Garovoy MR, Peterlin BM, Hunt CA (1997). Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys. Nucleic Acids Res, 25(3), 575-81.
  10. Li H, Yan G, Kern SE, Lim CS (2003). Correlation among agonist dose, rate of import, and transcriptional activity of liganded progesterone receptor B isoform in living cells. Pharm Res, 20(10), 1574-80.
  11. Davis JR, Kakar M, Lim CS (2007). Controlling protein compartmentalization to overcome disease. Pharm Res, 24(1), 17-27.
  12. Kakar M, Cadwallader AB, Davis JR, Lim CS (2007). Signal sequences for targeting of gene therapy products to subcellular compartments: the role of CRM1 in nucleocytoplasmic shuttling of the protein switch. Pharm Res, 24(11), 2146-55.
  13. Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS (2012). Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs. Pharm Res, 29(4), 1098-109.
  14. Constance JE, Despres SD, Nishida A, Lim CS (2012). Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells. Pharm Res, 29(8), 2317-28.
  15. Davis JR, Mossalam M, Lim CS (2012). Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction. Pharm Res, 29(12), 3455-63.
  16. Matissek KJ, Okal A, Mossalam M, Lim CS (2014). Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax. Pharm Res, 31(9), 2503-15.
  17. Okal A, Matissek KJ, Matissek SJ, Price R, Salama ME, Janat-Amsbury MM, Lim CS (2014). Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model. Gene Ther, 21(10), 903-12.
  18. Lim CS, Hunt CA (1997). Synthesis of DNA dumbbells: chemical vs. enzymatic ligation of self-complementary oligonucleotides. Nucleosides Nucleotides, 16(1-2), 41-51.
  19. Kanwal C, Mu S, Kern SE, Lim CS (2004). Bidirectional on/off switch for controlled targeting of proteins to subcellular compartments. J Control Release, 98(3), 379-93.
  20. Kakar M, Davis JR, Kern SE, Lim CS (2007). Optimizing the protein switch: altering nuclear import and export signals, and ligand binding domain. J Control Release, 120(3), 220-32.
  21. Dixon AS, Kakar M, Schneider KM, Constance JE, Paullin BC, Lim CS (2009). Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis. J Control Release, 140(3), 245-9.
  22. Kanwal C, Li H, Lim C (2002). Model system to study classical nuclear export signals. AAPS pharmSci, 4(3), E18.
  23. Cornillie SP, Bruno BJ, Lim CS, Cheatham TE 3r (2018). Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics. The journal of physical chemistry. B, 122(14), 3864-3875.
  24. Li H, Fidler ML, Lim C (2005). Effect of initial subcellular localization of progesterone receptor on import kinetics and transcriptional activity. Molecular pharmaceutics, 2(6), 509-18.
  25. Cadwallader AB, Rollins DE, Lim C (2010). Effect of anabolic-androgenic steroids and glucocorticoids on the kinetics of hAR and hGR nucleocytoplasmic translocation. Molecular pharmaceutics, 7(3), 689-98.
  26. Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE 3rd, Lim C (2012). Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis. Molecular pharmaceutics, 9(1), 187-95.
  27. Mossalam M, Matissek KJ, Okal A, Constance JE, Lim C (2012). Direct induction of apoptosis using an optimal mitochondrially targeted p53. Molecular pharmaceutics, 9(5), 1449-58.
  28. Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE 3rd, Lim C (2012). Correction to "improved coiled-coil design enhances interaction with bcr-abl and induces apoptosis". Molecular pharmaceutics, 9(5), 1535.
  29. Constance JE, Woessner DW, Matissek KJ, Mossalam M, Lim C (2012). Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. Molecular pharmaceutics, 9(11), 3318-29.
  30. Woessner DW, Lim C (2013). Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation. Molecular pharmaceutics, 10(1), 270-7.
  31. Davis JR, Mossalam M, Lim C (2013). Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2. Molecular pharmaceutics, 10(4), 1340-9.
  32. Reaz S, Mossalam M, Okal A, Lim C (2013). A single mutant, A276S of p53, turns the switch to apoptosis. Molecular pharmaceutics, 10(4), 1350-9.
  33. Miller GD, Woessner DW, Sirch MJ, Lim C (2013). Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML. Molecular pharmaceutics, 10(9), 3475-83.
  34. Okal A, Mossalam M, Matissek KJ, Dixon AS, Moos PJ, Lim C (2013). A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells. Molecular pharmaceutics, 10(10), 3922-33.
  35. Matissek KJ, Mossalam M, Okal A, Lim C (2013). The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria. Molecular pharmaceutics, 10(10), 3592-602.
  36. Okal A, Cornillie S, Matissek SJ, Matissek KJ, Cheatham TE 3rd, Lim C (2014). Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity. Molecular pharmaceutics, 11(7), 2442-52.
  37. Bruno BJ, Lim C (2015). Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide. Molecular pharmaceutics, 12(5), 1412-21.
  38. Lu P, Redd Bowman KE, Brown SM, Joklik-Mcleod M, Vander Mause ER, Nguyen HTN, Lim C (2019). p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy. Molecular pharmaceutics, 16(8), 3386-3398.
  39. Kakar M, Kanwal C, Davis JR, Li H, Lim C (2006). Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains. The AAPS journal, 8(4), E718-28.
  40. Mossalam M, Soto J, Lim CS, Abel E (2013). Solid phase synthesis of mitochondrial triphenylphosphonium-vitamin E metabolite using a lysine linker for reversal of oxidative stress. PloS one, 8(1), e53272.
  41. Lu P, Vander Mause ER, Redd Bowman KE, Brown SM, Ahne L, Lim C (2019). Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53. Journal of ovarian research, 12(1), 45.
  42. Bowman KR, Kim JH, Lim C (2019). Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer. Journal of ovarian research, 12(1), 38.

Review

  1. Hager GL, Lim CS, Elbi C, Baumann CT (2000). Trafficking of nuclear receptors in living cells. [Review]. J Steroid Biochem Mol Biol, 74, (5), 249-54.
  2. Baumann CT, Lim CS, Hager GL (1999). Intracellular localization and trafficking of steroid receptors. [Review]. Cell Biochem Biophys, 31, (2), 119-27.
  3. Miller GD, Bruno BJ, Lim C (2014). Resistant mutations in CML and Ph(+)ALL - role of ponatinib. Biologics, 8, 243-54.
  4. Mossalam M, Dixon AS, Lim C (2010). Controlling subcellular delivery to optimize therapeutic effect. Therapeutic delivery, 1(1), 169-93.
  5. Constance JE, Lim C (2012). Targeting malignant mitochondria with therapeutic peptides. Therapeutic delivery, 3(8), 961-79.
  6. Bruno BJ, Miller GD, Lim C (2013). Basics and recent advances in peptide and protein drug delivery. Therapeutic delivery, 4(11), 1443-67.